International Journal of Infertility & Fetal Medicine

Register      Login

VOLUME 7 , ISSUE 2 ( May-August, 2016 ) > List of Articles

CASE REPORT

Severe Early-onset Ovarian Hyperstimulation Syndrome following Use of GnRH Agonist Trigger along with Low-dose hCG

K Muthukumar, TK Aleyamma, Sumi Thomas

Citation Information : Muthukumar K, Aleyamma T, Thomas S. Severe Early-onset Ovarian Hyperstimulation Syndrome following Use of GnRH Agonist Trigger along with Low-dose hCG. Int J Infertil Fetal Med 2016; 7 (2):68-72.

DOI: 10.5005/jp-journals-10016-1131

Published Online: 00-08-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Thomas S, Kamath MS, Muthukumar K, Aleyamma TK. Severe Early-onset Ovarian Hyperstimulation Syndrome following Use of GnRH Agonist Trigger along with Low-dose hCG. Int J Infertil Fetal Med 2016;7(2):68-72.


PDF Share
  1. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006 Jan;85(1):112-120.
  2. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008 Jul-Aug;14(4):321-333.
  3. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 2003 Jan-Feb;9(1):77-96.
  4. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010 Jul;94(2):389-400.
  5. A new approach to the management of patients at risk of ovarian hyperstimulation in an in vitro fertilization programme. Hum Reprod 1991 Sep;6(8):1088-1091.
  6. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose hCG: a pilot study. Reprod Biomed Online 2009 May;18(5):630-634.
  7. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod 2011 Oct;26(12):3437-3442.
  8. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002 Feb;87(2):709-715.
  9. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010 Feb;93(3):847-854.
  10. Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril 2011 Jun;95(8):2715-2717.
  11. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013 Apr;28(9):2522-2528.
  12. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011 May 11;(5):CD001750.
  13. Gonadotropin-releasing hormone agonist versus hCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014 Oct;(10):CD008046.
  14. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 2011 Mar;17(4):510-524.
  15. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013 Jun;28(9):2511-2521.
  16. An OHSS free clinic by segmentation of IVF treatment. Hum Reprod 2011 Oct;26(10):2593-2597.
  17. Severe ovarian hyperstimulation syndrome after GnRH agonist trigger and freeze-all approach in GnRH antagonist protocol. Fertil Steril 2014 Apr;101(4):1008-1011.
  18. Gonadotropin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod Biomed Online 2014 Nov;29(5):541-544.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.